Wednesday, December 16, 2020
Types of Left Ventricular Hypertrophy (LVH)
Tuesday, December 15, 2020
COVID-19 Vaccine Development
The worldwide magnitude of the COVID-19 pandemic is ineffable; it is unsurprisingly compared to the Spanish flu pandemic, which ravaged the world during the First World War (adding fuel to the fire!). One of the pandemic's various positive impacts has been the unprecedented research collaboration and data sharing across the world. Such singular efforts made it possible to cut down the usual time to achieve an approved vaccine from 10+ years to less than a year.
To put things into perspective, it took 60 years from the
time of the first polio outbreak to developing its vaccine; in the case of
Ebola, it took 15 years. Vaccine candidates for SARS-CoV-1 and MERS did not receive
the necessary impetus to advance into fruition. However, with SARS-CoV-2, the
situation is very different. Global initiatives such as ACTIV (Accelerating
COVID-19 Therapeutic Interventions and Vaccines), a public-private partnership
comprising of bigwigs like CDC, FDA, EMA (European Medicines Agency), and
numerous leading biopharmaceutical enterprises. Another project on a similar
scale is Operation Warp Speed, which has invited comparison to the infamous
Manhattan Project.
What is an "ideal" COVID-19 vaccine? There are
three criteria from the immunological perspective: 1) It induces a robust humoral
immune response that produces long-lasting neutralizing antibodies against
SARS-CoV-2 antigens, 2) It generates a strong cell-mediated immunity that
includes the production of memory T cells, 3) It should be free of any serious
local or systemic adverse effects. Considering the logistics of vaccinating the entire world, there are three more criteria: 1) It should be easy to administer,
preferably in one or two doses, 2) It should be easy to produce on a
large-scale, 3) Its storage should be uncomplicated, ideally possible at room
temperature.
Let us discuss the vaccines that are currently in
development. We all have heard about a few of them in the news and social media,
namely, Pfizer, Moderna, Covaxin, Astra Zeneca, and so on. There are,
impressively, 125+ SARS-CoV-2 vaccines in development globally. Broadly,
there are six platforms currently being utilized for vaccine development –
3. Protein (Subunit vaccines)
4. Viral vector – replicating/non-replicating
(examples - Oxford/Astra Zeneca, Johnson & Johnson)
5. Live attenuated virus
6. Inactivated virus
Almost all of the above models have targeted the spike glycoprotein,
which is present on the surface of SARS-CoV-2, to interfere with the viral
entry into a cell.
This article is an oversimplified summary of the vaccine development process. I haven't covered the vaccine platforms, molecular targets, and vaccine candidates in detail. With the advent of vaccine administration, whether it's Pfizer's or any other, there will be a massive surge in vaccine-related information. There will be challenges at every step, from distribution to underdeveloped areas of the world to alleviate the concerns of the skeptical anti-vaxxers. Let us hope that these vaccines start the end of the pandemic.
-Vinayak
Sunday, December 13, 2020
Saturday, December 12, 2020
About the Pfizer BioNTech COVID-19 Vaccine trial
Emoticon game: Acute Liver Failure answers
COVID-19 and the increased risk of Parkinson's disease
Hi!
Currently posted in psychiatry, I was reading articles on Parkinson's disease and came through this important finding in context with the coronavirus disease.
Friday, December 11, 2020
Cosmetic surgery and Nontuberculous Mycobacterial infections
Conus medullaris syndrome vs. Cauda equina syndrome
Both of these are orthopedic/neurosurgical emergencies! But in general, CM syndrome is more severe than CE syndrome.
Here's a comparison between the two...
Guidelines for management of gout by ACR 2020
Hi!
Long time..
Urate-lowering therapy indications and important guidelines for management of gout, as updated by ACR in 2020:
Monday, December 7, 2020
TORCH syndrome + mnemonic
TORCH syndrome is caused by congenital infection by a group of infectious agents.
Respiratory fluoroquinolones
Why are moxifloxacin, gemifloxacin, and levofloxacin also known as respiratory fluoroquinolones?
Sunday, December 6, 2020
Saturday, December 5, 2020
Mechanical ventilation
Terms you need to know
1.
PaO2: Oxygen saturation in arterial blood (N = 80-100)
2.
PaCO2: Carbon Dioxide saturation in arterial
blood (N = 35 – 45)
3. FiO2: Fraction of inhaled O2 (N = 21% i.e. the fraction of O2 in atmosphere air which we inhale)
4.
PEEP: Positive End Expiratory Pressure – The pressure needed at the end of expiration to keep the alveoli open.
5.
RR: Respiratory rate (N = 12-16)
6. TV: Tidal Volume (N = 6-8 ml/kg = approx. 500 ml)
Thursday, November 26, 2020
Thursday, November 19, 2020
When should you start sodium bicarbonate in CKD patients? Mnemonic
Monday, November 16, 2020
Neurology examination template
Here is my template for documenting the basic bare minimum neurology examination.
Saturday, November 7, 2020
It's a Carny Problem
Carney's Triad - ENCHONDROMA + PARAADRENAL GANGLIOMA + GIST
Friday, November 6, 2020
Blood Donation
BLOOD DONATION
PRE-DONATION
HISTORY:
- Men can donate safely once every three months while women can donate every four months
- Age between 18 and 60 years
- The donor should be in a healthy state of mind and body
- Past one year - not been treated for Rabies or received Hepatitis B immune globulin
- Past six months - not had a tattoo, ear or skin piercing or acupuncture, not received blood or blood products, no serious illness or major surgery, no contact with a person with hepatitis or yellow jaundice.
- Past three months - not donated blood or been treated for Malaria
- Past one month - had any immunizations
- Past 72 hours - had dental work or taken Aspirin
- Past 48 hours - taken any antibiotics or any other medications (Allopathic or Ayurveda or Siddha or Homeopathy)
- Past 24 hours - taken alcoholic beverages
- Presently - not suffering from cough, influenza or sore throat, the common cold
- Women should not be pregnant or breastfeeding her child or menstruating.
- No diabetes, chest pain, heart disease or high BP, cancer, blood clotting problem or blood disease, unexplained fever weight loss, fatigue, night sweats, enlarged lymph nodes in armpits, neck or groin, white patches in the mouth, etc.
- No history of TB, bronchial asthma or allergic disorder, liver disease, kidney disease, fits or fainting, blue or purple spots on the skin or mucous membranes, received human pituitary - growth hormones, etc.
EXAMINATION:
- Temperature - Normal (oral temperature not exceeding 37.50 C)
- Pulse - between 50 and 100/minute with no irregularities
- Blood Pressure -Systolic 100-180 mm Hg and Diastolic 50 - 100 mm Hg
- Bodyweight - not less than 45 Kg
- Hemoglobin - not less than 12.5 g/dL-
Procedure to measure Hb using CuSO4:
i) Massage the finger to be pricked (preferably ring finger)
ii) Disinfect it
iii) Prick using disposable needle/ lancet
iv) Put the drop of blood in CuSO4 containing beaker
v) If the blood drop sinks, Hb is more than 12.5, hence the person can donate blood (provided no other contraindication).
PROCEDURE:
- Identify donor and label blood collection bag and test tubes
- Ask the donor to state their full name
- Ensure that:
- the blood collection bag is of the correct type;
- the labels on the blood collection bag and all its satellite bags, sample tubes and donor records have the correct patient name and number;
- the information on the labels matches with the donor's information
- Select a large, firm vein, preferably in the antecubital fossa, from an area free from skin lesions or scars
- Clean the site of venepuncture by alcohol and let it dry
- Perform phlebotomy using a 16-gauge needle, which is usually attached to the blood collection bag. Use of a retractable needle or safety needle with a needle cover is preferred if available, but all should be cut off at the end of the procedure.
- Ask the donor to open and close the fist slowly every 10–12 seconds during collection
- Remove the tourniquet when the blood flow is established or after 2 minutes, whichever comes first
- Ask the patient to squeeze a ball intermittently during the procedure
- Monitor the donor and the donated unit
- Remove the needle and collect samples
- Cut off the needle using a sterile pair of scissors
- Collect blood samples for laboratory testing
POST-PROCEDURE:
DONOR CARE:
- ask the donor to remain in the chair and relax for a few minutes
- inspect the venepuncture site; if it is not bleeding, apply a bandage to the site; if it is bleeding, apply further pressure
- ask the donor to sit up slowly and ask how the person is feeling
- before the donor leaves the donation room, ensure that the person can stand up without dizziness and without a drop in blood pressure
- offer the donor some refreshments
BLOOD UNIT AND SAMPLES:
- Transfer the blood unit to a proper storage container according to the blood center requirements and the product
- Ensure that collected blood samples are stored and delivered to the laboratory with completed documentation, at the recommended temperature, and in a leakproof, closed container
REFERENCES:
http://naco.gov.in/blood-transfusion-services-publications
Written by our guest authors HARSH JOGI and AYUSHI GUPTA


